A randomized, double-blind, placebo-controlled study is evaluating the safety and tolerability of IBI3002 in healthy participants and asthma patients.

ClinicalAugust 4, 2026

Study on Fluticasone Propionate/Albuterol Combination for Asthma Exacerbation Prevention

The study aims to evaluate the efficacy of a fixed-dose combination of fluticasone propionate and albuterol sulfate in preventing severe asthma exacerbations over a treatment period of up to 42 months.

RegulatoryAugust 2, 2026

Resmed Issues Correction for Astral Ventilator Due to Electrical Component Failure

Resmed has issued a correction for certain Astral ventilators due to a failure of an electrical component that may lead to therapy interruption or failure.

CompetitiveAugust 1, 2026

Cipla's ANDA213087 for Fluticasone Propionate and Salmeterol Xinafoate Receives AP Status

Cipla's application ANDA213087 for Fluticasone Propionate and Salmeterol Xinafoate has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJuly 31, 2026

FDA Submission Update for Breztri Aerosphere by AstraZeneca

AstraZeneca's Breztri Aerosphere (NDA212122) has a submission status of Approved (AP) with a standard review priority.

RegulatoryJuly 31, 2026

FDA Acceptance of SYMBICORT AEROSPHERE Supplement by AstraZeneca

The FDA has accepted the supplemental NDA for SYMBICORT AEROSPHERE, indicating a step forward in its regulatory process.

CompetitiveJuly 31, 2026

GRANITE Study Evaluates Airsupra vs Albuterol for Asthma Exacerbation Risk

The GRANITE study is assessing the real-world effectiveness of Airsupra compared to albuterol in reducing asthma exacerbations.

RegulatoryJuly 29, 2026

FDA Accepts Application for Budesonide and Formoterol Fumarate Dihydrate

The FDA has accepted the application ANDA212212 for Budesonide and Formoterol Fumarate Dihydrate submitted by Teva Pharmaceuticals.

RegulatoryJuly 28, 2026

Cipla's Albuterol Sulfate ANDA219409 Receives FDA Approval Status

Cipla's application for Albuterol Sulfate (ANDA219409) has received an approval status of AP from the FDA.

ClinicalJuly 24, 2026

Qufeng Xuanbi Formula shows potential in treating allergic asthma via immune-metabolic regulation

Qufeng Xuanbi Formula has demonstrated anti-asthmatic activity and may influence airway remodeling through metabolic pathways.

StrategyJuly 24, 2026

Study Reveals Mechanism of Herbal Extracts in Treating Acute Lung Injury in Poultry

The study identifies that Lonicerae Japonicae Flos and Forsythiae Fructus extracts alleviate LPS-induced acute lung injury in broilers by suppressing MAPK signaling and regulating apoptosis.

ClinicalJuly 23, 2026

Study on Diaphragm Dysfunction During Mechanical Ventilation Initiated

A study is evaluating diaphragm activity and its relationship to ventilator-induced diaphragm dysfunction over 7 days.

ClinicalJuly 23, 2026

Study on Buteyko Breathing Technique's Impact on Childhood Asthma Control

A study is examining the effect of the Buteyko breathing technique on asthma control and quality of life in children aged 7-12.

RegulatoryJuly 22, 2026

MHRA Approves First Lower-Carbon Beclometasone Inhalers for Asthma

The MHRA has approved the world's first lower-carbon beclometasone inhalers, utilizing a next-generation propellant.

ClinicalJuly 21, 2026

Trial on High Flow Oxygen Therapy for Hypoxemic Respiratory Distress Initiated

A clinical trial is underway to assess the effectiveness of adjusting high-flow oxygen therapy based on lung volume measurements in ICU patients with hypoxemic respiratory distress.

RegulatoryJuly 20, 2026

Nephron's Levalbuterol Hydrochloride ANDA215217 Receives Approval Status

Nephron's ANDA for Levalbuterol Hydrochloride has received an approval status (AP) from the FDA.

StrategyJuly 19, 2026

FDA Grants Approval for Glycopyrrolate ANDA216910 by Quagen

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Glycopyrrolate submitted by Quagen.

ClinicalJuly 18, 2026

Telemonitoring Program Shows Promise for COPD Management

A telemonitoring program is being tested for its effectiveness in improving clinical outcomes and reducing hospitalizations in COPD patients.

RegulatoryJuly 18, 2026

Lupin Inc. Submits ANDA for Revefenacin to FDA

Lupin Inc. has submitted an Abbreviated New Drug Application (ANDA) for Revefenacin, currently under standard review.

RegulatoryJuly 17, 2026

FDA Approves TRIMBOW (NDA219622) by Chiesi

The FDA has approved TRIMBOW, a combination inhaler containing beclomethasone dipropionate, formoterol fumarate, and glycopyrrolate.

RegulatoryJuly 16, 2026

Resmed Astral Ventilators Face Serious Electrical Component Failure Risk

Certain Astral ventilators from Resmed may experience electrical component failures, risking serious injury or death.

RegulatoryJuly 16, 2026

FDA Accepts Supplemental Application for Fasenra (Benralizumab) by AstraZeneca

The FDA has accepted a supplemental application for Fasenra (benralizumab) from AstraZeneca.

ClinicalJuly 16, 2026

RESET-COPD Study to Develop Early Warning Model for COPD Exacerbations

A multicenter study is underway to validate a multisensor-based monitoring model for COPD patients on home NPPV.

StrategyJuly 15, 2026

Baxter Issues Correction for Volera Positive Pressure Breathing Devices Due to Air Leakage

Baxter has issued a correction for the Volera system due to potential air and medication leakage, which can compromise patient therapy.

RegulatoryJuly 15, 2026

FDA Accepts Supplement for TUXARIN ER by MAINPOINTE

The FDA has accepted a supplemental application for TUXARIN ER, which contains chlorpheniramine maleate and codeine phosphate.

StrategyJuly 15, 2026

FDA Grants Approval for Ephedrine Sulfate ANDA216740 by Baxter Healthcare

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) for Ephedrine Sulfate submitted by Baxter Healthcare.

ClinicalJuly 15, 2026

Culturally Adapted Snacktivity™ Program Trial for COPD Patients Launched

A clinical trial is underway to evaluate the effectiveness of a culturally adapted Snacktivity™ program on cognition and self-care in COPD patients.

ClinicalJuly 13, 2026

Study on Inhaled Nitric Oxide's Impact on COPD Patients' Breathing Efficiency

A study is investigating the effects of inhaled nitric oxide on lung blood vessel function and breathing efficiency in COPD patients.

RegulatoryJuly 6, 2026

FDA Approves Supplemental Application for Breztri Aerosphere

The FDA has approved a supplemental application for Breztri Aerosphere, containing budesonide, formoterol fumarate, and glycopyrrolate.

RegulatoryJuly 6, 2026

FDA Accepts Supplemental Application for SYMBICORT AEROSPHERE

The FDA has accepted a supplemental application for SYMBICORT AEROSPHERE, indicating progress in its regulatory review.

StrategyJuly 5, 2026

Teva's Budesonide and Formoterol Fumarate Dihydrate Receives FDA Approval

Teva Pharmaceuticals has received FDA approval for ANDA212212, a generic formulation of Budesonide and Formoterol Fumarate Dihydrate.

RegulatoryJuly 5, 2026

Cipla's Albuterol Sulfate ANDA219409 Receives AP Status from FDA

Cipla's application for Albuterol Sulfate has received an Abbreviated Approval (AP) status from the FDA.

ClinicalJuly 4, 2026

AstraZeneca's PT010 Study Targets Severe Asthma in Adults and Adolescents

AstraZeneca is conducting a study to evaluate the efficacy and safety of PT010, a combination inhaler, in patients with inadequately controlled severe asthma.

CompetitiveJuly 3, 2026

Study Compares Ultrasonic vs Conventional Spirometry in Chronic Respiratory Disease

A study is underway to compare the accuracy of a handheld ultrasonic spirometer against a standard hospital spirometer in adults with chronic respiratory diseases.

ClinicalJuly 1, 2026

Fluticasone Propionate Nebulized Suspension Trial for Infant Wheezing Shows Potential

A clinical trial is underway to evaluate the efficacy and safety of fluticasone propionate nebulized suspension in infants with acute wheezing.

ClinicalJune 29, 2026

Study on Near Fatal Asthma in Children to Inform Future Clinical Guidelines

A study led by the University of Edinburgh will investigate the frequency and risk factors of near fatal asthma in children aged 5-15 in the UK and ROI.

ClinicalJune 28, 2026

MiNK Therapeutics Trials agenT-797 for Severe Pneumonia with AHRF

MiNK Therapeutics is conducting a clinical trial to assess the efficacy of agenT-797 in combination with standard care for severe pneumonia and acute hypoxemic respiratory failure.

RegulatoryJune 27, 2026

Rubicon Research's ANDA220869 for Promethazine and Dextromethorphan Receives AP Status

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status to Rubicon Research for a combination of Promethazine Hydrochloride and Dextromethorphan Hydrobromide.

ClinicalJune 26, 2026

AstraZeneca initiates Phase 3 extension study for Tozorakimab in COPD patients

AstraZeneca is conducting Phase 3 extension study to evaluate the long-term efficacy and safety of Tozorakimab in COPD patients with a history of exacerbations.

ClinicalJune 25, 2026

Study on TGF-beta's Role in Asthmatic Susceptibility to RSV Initiated

A clinical trial is investigating the role of TGF-beta in increasing susceptibility to RSV in individuals with asthma.

CompetitiveJune 25, 2026

Phase 2 Study of Rademikibart for Acute Asthma Exacerbation Initiated by Connect Biopharm

Connect Biopharm has initiated Phase 2 trial for Rademikibart as an add-on treatment for acute asthma exacerbations.

ClinicalJune 24, 2026

CHARM-COPD Program Evaluates Post-Discharge Care for COPD Patients

The CHARM-COPD program aims to assess the feasibility and acceptability of a care program for COPD patients post-discharge.

RegulatoryJune 22, 2026

FDA Accepts Supplement for Provocholine (Methacholine Chloride)

The FDA has accepted a supplemental application for Provocholine, indicating ongoing regulatory progress.

ClinicalJune 22, 2026

University of Edinburgh Investigates Innate Immunity Mechanisms in COPD

The study aims to understand the metabolic dysfunction of immune cells in COPD patients and its impact on bacterial clearance.

RegulatoryJune 22, 2026

Baxter's Volara System Faces Air Leak Issues Impacting Patient Therapy

The Volara system's patient circuits may leak air and medication, compromising therapy effectiveness.

RegulatoryJune 22, 2026

Beekeeper’s Naturals Recalls Saline Nasal Spray Due to Microbial Contamination

Beekeeper’s Naturals is recalling a specific lot of Saline Nasal Spray due to microbial contamination.

ClinicalJune 21, 2026

Amgen's AMG 691 Phase 1 Study Targets Safety in Asthma Patients

Amgen is conducting Phase 1 study to evaluate the safety and tolerability of AMG 691 in healthy participants and those with mild-to-moderate asthma.

StrategyJune 21, 2026

Budget Impact of Single-Inhaler Triple Therapy for Asthma in Saudi Arabia

The study evaluates the financial implications of introducing FF/UMEC/VI therapy for asthma in Saudi Arabia.

RegulatoryJune 21, 2026

FDA Accepts Supplement for Provocholine (Methacholine Chloride) by Methapharm

The FDA has accepted a supplemental application for Provocholine, indicating ongoing regulatory progress.

StrategyJune 20, 2026

FDA Approves Albuterol Sulfate ANDA219409 from Cipla

The FDA has approved ANDA219409 for Albuterol Sulfate submitted by Cipla.

ClinicalJune 18, 2026

Study Reveals Mucus-Plug Dynamics in COPD Patients and Ex-Smokers

In a study of ex-smokers, mucus-plugs persisted in one-third of patients with COPD, while new plugs developed in others, indicating complex dynamics.

ClinicalJune 18, 2026

EVOLVE Study to Assess Real-World Effectiveness of Tezepelumab in Severe Asthma in Greece

The EVOLVE study will evaluate the real-world effectiveness of tezepelumab in uncontrolled severe asthma over two years in Greece.

CompetitiveJune 17, 2026

Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough

A Phase 3 study is underway to evaluate the efficacy and safety of BLU-5937 in adults with refractory chronic cough.

ClinicalJune 16, 2026

Tozorakimab Shows Positive Phase III Results in COPD, Reducing Exacerbations

Tozorakimab met its primary endpoint in the Phase III MIRANDA trial, showing significant reduction in COPD exacerbations.

ClinicalJune 2, 2026

Tozorakimab achieves primary endpoints in Phase III trials for COPD

Tozorakimab met primary endpoints in both OBERON and TITANIA Phase III trials, showing significant reductions in COPD exacerbations.

ClinicalJune 1, 2026

Study on NMES for Functional Recovery in COPD and Pneumonia Patients

A clinical trial is investigating the feasibility of neuromuscular electrical stimulation (NMES) to improve recovery in older adults with AECOPD and community-acquired pneumonia.

RegulatoryJune 1, 2026

Breztri Gains US Approval as First Triple Therapy for Asthma

Breztri has been approved in the US as the first and only triple therapy for asthma in patients aged 12 and older, based on positive Phase III trial results.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Asthma →

Chronic Obstructive Pulmonary Disease (COPD) →

Chronic Respiratory Disease →

COPD →

Wheezing Diseases →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.